List view / Grid view
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
A preclinical study conducted by researchers at Weill Cornell Medicine have demonstrated a new gene-editing strategy to treat short bowel syndrome (SBS), a life-threatening condition in which patients lack a functional small intestine.
Rutgers researchers have discovered new insights into how polycystic kidney disease (PKD) progresses, which could lead to more targeted treatments. This breakthrough may help improve therapies for PKD patients in the future.
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer's disease before symptoms emerge, an approach that could revolutionise treatment strategies, offering new hope for at-risk individuals.
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
The discovery from researchers at Johns Hopkins Medicine reveals how bacteria use the CRISPR-Cas system to store viral DNA, enhancing their immunity against future infections, and potentially paving the way for new phage-based therapies
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
